These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 22109892

  • 21. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
    Li X, Liao J, Park SI, Koh AJ, Sadler WD, Pienta KJ, Rosol TJ, McCauley LK.
    Bone; 2011 Jun 01; 48(6):1354-61. PubMed ID: 21419883
    [Abstract] [Full Text] [Related]

  • 22. Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy.
    Kuroshima S, Mecano RB, Tanoue R, Koi K, Yamashita J.
    J Periodontol; 2014 Jan 01; 85(1):24-33. PubMed ID: 23688101
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition.
    Casanova M, Herelle J, Thomas M, Softley R, Schindeler A, Little D, Schneider P, Müller R.
    Bone; 2016 Nov 01; 92():70-78. PubMed ID: 27542660
    [Abstract] [Full Text] [Related]

  • 25. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.
    Smith EJ, McEvoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM.
    J Bone Miner Res; 2004 Oct 01; 19(10):1698-705. PubMed ID: 15355565
    [Abstract] [Full Text] [Related]

  • 26. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
    Amanat N, McDonald M, Godfrey C, Bilston L, Little D.
    J Bone Miner Res; 2007 Jun 01; 22(6):867-76. PubMed ID: 17371160
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.
    Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E.
    Haematologica; 2009 May 01; 94(5):725-8. PubMed ID: 19407319
    [Abstract] [Full Text] [Related]

  • 29. Zoledronic acid decreases bone formation without causing osteocyte death in mice.
    Huja SS, Fernandez SA, Phillips C, Li Y.
    Arch Oral Biol; 2009 Sep 01; 54(9):851-6. PubMed ID: 19591974
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
    Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ.
    Biol Blood Marrow Transplant; 2013 Sep 01; 19(9):1361-7. PubMed ID: 23806773
    [Abstract] [Full Text] [Related]

  • 32. Transgenic overexpression of tartrate-resistant acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density.
    Gradin P, Hollberg K, Cassady AI, Lång P, Andersson G.
    Cells Tissues Organs; 2012 Sep 01; 196(1):68-81. PubMed ID: 22248481
    [Abstract] [Full Text] [Related]

  • 33. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
    Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K.
    Bone; 2009 May 01; 44(5):908-16. PubMed ID: 19442620
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.
    Liu H, Cui J, Sun J, Du J, Feng W, Sun B, Li J, Han X, Liu B, Yimin, Oda K, Amizuka N, Li M.
    J Mol Histol; 2015 Jun 01; 46(3):313-23. PubMed ID: 25969354
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Conversion of immunosuppressive monotherapy from cyclosporin a to tacrolimus reverses bone loss in rats.
    Spolidorio LC, Nassar PO, Nassar CA, Spolidorio DM, Muscará MN.
    Calcif Tissue Int; 2007 Aug 01; 81(2):114-23. PubMed ID: 17612778
    [Abstract] [Full Text] [Related]

  • 39. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
    Qiao H, Wang TY, Yu ZF, Han XG, Liu XQ, Wang YG, Fan QM, Qin A, Tang TT.
    Cell Death Dis; 2016 Feb 11; 7(2):e2094. PubMed ID: 26866274
    [Abstract] [Full Text] [Related]

  • 40. Alendronate therapy in cyclosporine-induced alveolar bone loss in rats.
    Spolidorio LC, Marcantonio E, Spolidorio DM, Nassar CA, Nassar PO, Marcantonio RA, Rossa C.
    J Periodontal Res; 2007 Oct 11; 42(5):466-73. PubMed ID: 17760825
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.